Jeil Pharmaceutical Co.,Ltd (KRX:271980)
South Korea
· Delayed Price · Currency is KRW 11,200
+30 (0.27%)
Feb 20, 2025, 9:00 AM KST
KRX:271980 Revenue
Jeil Pharmaceutical Co.,Ltd had revenue of 174.38B KRW in the quarter ending September 30, 2024, a decrease of -1.59%. This brings the company's revenue in the last twelve months to 697.64B, down -2.86% year-over-year. In the year 2023, Jeil Pharmaceutical Co.,Ltd had annual revenue of 726.39B with 0.58% growth.
Revenue (ttm)
697.64B
Revenue Growth
-2.86%
P/S Ratio
0.24
Revenue / Employee
697.64M
Employees
1,000
Market Cap
164.66B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 726.39B | 4.16B | 0.58% |
| Dec 31, 2022 | 722.23B | 21.54B | 3.07% |
| Dec 31, 2021 | 700.69B | 9.37B | 1.36% |
| Dec 31, 2020 | 691.32B | 19.92B | 2.97% |
| Dec 31, 2019 | 671.41B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4,364.39B |
| Celltrion | 2,876.25B |
| Yuhan | 2,008.84B |
| SK Biopharmaceuticals | 511.33B |
| SK bioscience | 201.30B |
| Hanmi Pharm. | 1,495.50B |
| Hanmi Science | 1,283.65B |
| Hanall Biopharma | 134.24B |